News | Women's Health | August 17, 2015

Regional Node Irradiation Beneficial for Stage I-III Breast Cancer Patients

European study finds overall survival improved at 10-year follow-up

breast cancer, stage I-III, irradiation, regional nodes, EORTC, Philip Poortmans

Ryan Tobin Photography for Densitas Inc.

August 17, 2015 — Patients with stage I, II or III breast cancer see marginal benefit on overall survival with irradiation of regional nodes, according to a new study from the European Organisation for Research and Treatment of Cancer (EORTC). Conducted at a median follow-up of 10.9 years, the study found that overall survival was 82.3 percent for regional irradiation versus 80.7 percent for no regional irradiation (HR=0.87 (95%CI: 0.76, 1.00), p=0.06).

The results, published in the New England Journal of Medicine, also showed that disease-free survival, distant-disease-free survival and breast cancer mortality were significantly improved. Side effects were very limited, although very long-term toxicity of radiation remains unknown.

The phase III EORTC 22922-10925 trial was conducted to evaluate what effect regional node irradiation — i.e., irradiation of the internal mammary and medial supraclavicular lymph nodes — would add to whole breast or chest wall irradiation following surgery in patients with stage I, II, and III breast cancer.

Prof. Philip Poortmans of the Radboud university medical center, Nijmegen, The Netherlands said: "We became interested in the role that elective regional radiation therapy might play following the publication of several studies that showed conflicting results of this treatment: one, an increased long-term mortality due to cardiac causes following outdated irradiation techniques; two, that loco-regional post-mastectomy radiation therapy had a favorable effect on disease-related endpoints; and three, that improved irradiation techniques led to lower cardiac exposure. Therefore, our study was highly needed to address the existing uncertainties concerning the role of lymph node irradiation. The results are very important as they show a clinically relevant decrease in distant-disease-free and disease-free survival, which points to the fact that the effect of radiation therapy should not only be measured by the influence on loco-regional control. Moreover, we expect that the currently modest benefit on overall survival will increase with longer follow-up, especially as we did not at all see any increase in other causes of death than cancer after regional irradiation."

From 1996 through 2004, this randomized trial coordinated by the EORTC Radiation Oncology and Breast Cancer Groups accrued 4,004 patients with either positive axillary lymph nodes or, in the case of tumor-free lymph nodes, centrally or medially located primary tumors. The investigators concluded that regional irradiation does benefit patients with early stage breast cancer, but they also point out that these data are not applicable to patients with laterally located node-negative cancers, the largest patient subgroup in industrialized countries. They plan to continue trial monitoring for up to 20 years median follow-up.

For more information: www.eortc.org

Related Content

BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Overlay Init